Shares of Edge Therapeutics posted a solid gain in Wednesday’s trading session after the company announced that it would be conducting a registered direct offering of its common stock.
Audentes Therapeutics saw its shares drop early on Wednesday after the company announced the pricing of its secondary offering.
Over the past five, 10 and 20 years, the life science and bioproduction segments have tended to outperform the S&P 500 more often than not.
Arena Pharmaceuticals saw its shares drop sharply on Tuesday after the company announced a secondary offering of 60 million shares of its common stock.
Health care giant Johnson & Johnson missed sales estimates but beat analysts' profit target. The $30 billion acquisition of Actelion has been included in revised guidance for the 2017 fiscal year.
Exiting the ACA individual exchanges boosted UnitedHealth's profit while nipping its revenues and subscriber numbers. The company also raised its outlook for full-year revenues and profits.
Hospital services provider HCA announced disappointing preliminary financial results for the first quarter of 2017. Shares tumbled more than 3% at the opening bell.
When drugs are expected to get FDA approval and show positive data but don't, the underlying stocks of drug and biotech companies can see harsh punishment.
With interest rates once again dropping as the geopolitical worries ratchet up, investors are concerned about owning good stocks and receiving dependable dividends. One place that looks very good now is pharmaceuticals.
Sorrento Therapeutics saw its shares plunge on Thursday after the company announced a secondary offering.
Neurocrine Biosciences saw its shares jump after the company reported that the FDA had approved Ingrezza capsules for the treatment of adults with tardive dyskinesia.
The March 31 short interest data have been compared with the previous report, and short interest decreased in most of the selected biotech stocks.
The March 31 short interest data have been compared with the previous figures, and short interest decreased in most of these selected pharmaceutical stocks.
Several analysts and market pundits have been positive toward Eli Lilly lately, including now a price target raise at JPMorgan.
A letter from the FDA citing deficiencies in its treatment for moderate to severe dysparaeunia due to vulvar vaginal atrophy had a negative impact on TherapeuticsMD stock, but it was not a death sentence…
